Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly's revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a full portfolio of other products, and some increased revenue in the doubl...
Jim Cramer looks at Eli Lilly's outlook as the company's Alzheimer drug goes through FDA
'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.
Eli Lilly may have developed the greatest drug of all time, says Jim Cramer
'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.
Here's Why Eli Lilly Will Likely Announce a Stock Split
24/7 Wall Street Insights Unlike the declining stocks of some of its pharmaceutical rivals, Eli Lilly has continually beat analysts' forecasts and prospered accordingly.
Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab
Eli Lilly (LLY) shares gained more than 2% in extended trading on Monday after a panel of independent advisors to the Food and Drug Administration (FDA) unanimously recommended the pharmaceutical g...
Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference
Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 4:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President of Lilly ...
FDA advisers say Eli Lilly Alzheimer's treatment is effective
Dr. Scott Gottlieb, Former FDA Commissioner, joins 'Closing Bell Overtime' to talk news that the FDA has deemed Eli Lilly's Alzheimers treatment as effective.
Eli Lilly exec expects obesity pill data in April 2025
Data from Eli Lilly's late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly executive said on Monday.
Eli Lilly's Alzheimer's drug gets backing from FDA advisers
Eli Lilly & Co.'s experimental Alzheimer's drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Admi...
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
A top Eli Lilly executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.
Eli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared Holz
Jared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss the FDA's review of Eli Lilly's experimental Alzheimer drug, whether the drug is a game changer, and more.
US FDA advisers to review Eli Lilly Alzheimer's drug
An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's experimental Alzheimer's drug donanemab.
The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?
Corporations pay large sums to the NBA and WNBA to have their company logos featured as patches on jerseys. This strategy makes sense because it helps brands attract attention from fans watching ga...
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine INDIANAPOLIS , June 8, 2...
Related Companies